In prostate cancer, proteases are well known to regulate cell proliferation and death, tumor invasion, metastasis, and angiogenesis. Proteolysis is also essential for normal and tumor-induced bone remodeling. Although protease inhibitors have been tested in some patients with cancer, none have entered into clinical trials specifically for patients with bone metastasis. We must apply a broad and comprehensive strategy to choose the appropriate protease targets specific for bone metastasis, and we must improve our understanding of the interplay between tumor cells and bone with regard to protease activity in the bone microenvironment. We must also develop systems for monitoring the inhibition of proteases as a key endpoint in clinical trials. Therefore, our Specific Aims are to: (1) Analyze the effects of prostate tumor cell-bone interactions on the proteolysis associated with prostate cancer bone metastases; (2) confirm that the proteases identified in the organotypic model system of Aim 1 are expressed and active during the colonization of bone by prostate cancer cells in vivo; (3) validate that the protease classes and individual proteases identified above contribute to the proteolysis induced by prostate tumor cell-bone interactions; and (4) use protease-activated probes to image both activities of proteases validated as contributing to prostate cancer bone metastasis as well as the abrogation of those activities by protease inhibitors. To accomplish these goals will use novel bone organotypic models, bone metastasis models, and clinical human bone metastasis tissues. Gene profiling methods will be used to monitor changes in protease gene expression in tumor and bone marrow stromal cells. Prostate cancer-induced proteolysis of bone or relevant substrates will be monitored, and a variety of methods will be used to measure and visualize activity of individual proteases. The roles of specific stromal-derived proteases in bone metastasis models will be examined using general and specific protease inhibitors and as well as cells, bones, and mice rendered genetically null for specific proteases. As clinical trials with protease inhibitors will be more informative if protease activity can be monitored non-invasively, we will validate protease-activated imaging probes for their ability to selectively image protease activity and its abrogation by protease inhibitors in both in vitro and in vivo models of prostate cancer bone metastasis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK067687-01
Application #
6685356
Study Section
Special Emphasis Panel (ZCA1-SRRB-U (M2))
Program Officer
Malozowski, Saul N
Project Start
2003-09-25
Project End
2008-08-31
Budget Start
2003-09-25
Budget End
2004-08-31
Support Year
1
Fiscal Year
2003
Total Cost
$469,709
Indirect Cost
Name
Wayne State University
Department
Urology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Sabbota, Aaron L; Kim, Hyeong-Reh Choi; Zhe, Xiaoning et al. (2010) Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 70:5558-66
Chinni, Sreenivasa R; Yamamoto, Hamilto; Dong, Zhong et al. (2008) CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 6:446-57
Bonfil, R Daniel; Dong, Zhong; Trindade Filho, J Carlos et al. (2007) Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 170:2100-11
Bonfil, R Daniel; Sabbota, Aaron; Nabha, Sanaa et al. (2006) Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer 118:2721-6
Li, Yiwei; Kucuk, Omer; Hussain, Maha et al. (2006) Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 66:4816-25
Nabha, Sanaa M; Bonfil, R Daniel; Yamamoto, Hamilto A et al. (2006) Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis. Clin Exp Metastasis 23:335-44
Sloane, Bonnie F; Yan, Shiqing; Podgorski, Izabela et al. (2005) Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol 15:149-57